X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (44) 44
oncology (33) 33
humans (32) 32
1st-in-human (30) 30
1st-in-human phase-i (26) 26
cancer (19) 19
pharmacology & pharmacy (13) 13
animals (11) 11
male (10) 10
advanced solid tumors (9) 9
care and treatment (9) 9
clinical trials (9) 9
female (9) 9
dose-escalation (8) 8
medical research (8) 8
review (8) 8
tumors (8) 8
double-blind (7) 7
health aspects (7) 7
medicine & public health (7) 7
middle aged (7) 7
neoplasms - drug therapy (7) 7
phase-i (7) 7
adult (6) 6
analysis (6) 6
antineoplastic agents - therapeutic use (6) 6
immunotherapy (6) 6
medicine, experimental (6) 6
monoclonal antibodies (6) 6
mutation (6) 6
pharmacokinetics (6) 6
pi3k inhibitor (6) 6
safety (6) 6
signal transduction (6) 6
solid tumors (6) 6
aged (5) 5
cell biology (5) 5
hematology (5) 5
inhibitors (5) 5
neoplasms. tumors. oncology. including cancer and carcinogens (5) 5
pathway (5) 5
pharmacodynamics (5) 5
pharmacology/toxicology (5) 5
proteins (5) 5
research (5) 5
1-phosphatidylinositol 3-kinase (4) 4
1st-in-human clinical-trials (4) 4
akt (4) 4
antibodies (4) 4
bay 80-6946 (4) 4
biochemistry & molecular biology (4) 4
chemotherapy (4) 4
drug development (4) 4
drug therapy (4) 4
i dose-escalation (4) 4
immunogenicity (4) 4
kinases (4) 4
mammalian target (4) 4
maximum tolerated dose (4) 4
medical colleges (4) 4
medicine, research & experimental (4) 4
melanoma (4) 4
mice (4) 4
molecular targeted therapy (4) 4
neoplasms - pathology (4) 4
open-label (4) 4
original (4) 4
patients (4) 4
pharmacology (4) 4
phosphoinositide 3-kinase (4) 4
protein kinase inhibitors - pharmacology (4) 4
protein kinase inhibitors - therapeutic use (4) 4
studies (4) 4
t cells (4) 4
therapeutic proteins (4) 4
treatment outcome (4) 4
acquired-resistance (3) 3
activation (3) 3
akt protein (3) 3
allometric scaling (3) 3
antibodies, monoclonal - therapeutic use (3) 3
biochemistry, general (3) 3
biodistribution (3) 3
biomarkers (3) 3
biomedicine (3) 3
breast cancer (3) 3
buparlisib bkm120 (3) 3
cancer research (3) 3
cells (3) 3
chemistry, medicinal (3) 3
chronic lymphocytic-leukemia (3) 3
copanlisib (3) 3
dose selection (3) 3
dose-response relationship, drug (3) 3
dosing (3) 3
drug design (3) 3
drug dosages (3) 3
drug evaluation, preclinical - methods (3) 3
drugs (3) 3
expression (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 10, pp. 2559 - 2566
Background: Lurbinectedin (PM01183) has synergistic antitumor activity when combined with doxorubicin in mice with xenografted tumors. This phase I trial... 
Phase I study | Lurbinectedin | PM01183 | Small-cell lung cancer | TRIAL | small-cell lung cancer | SOLID TUMORS | ONCOLOGY | TOPOTECAN | lurbinectedin | OPEN-LABEL | phase I study | 1ST-IN-HUMAN | Index Medicus | Original | Editor's Choice
Journal Article
European Journal of Cancer, ISSN 0959-8049, 10/2019, Volume 120, pp. 40 - 46
Determining the optimal biological dose (OBD) has been described as an alternative strategy to the maximum tolerated doses (MTDs) for identifying the... 
Drug | Antibodies | Maximum tolerated dose | Monoclonal | Anti-neoplastic agents | Dose-response relationship | HISTONE DEACETYLASE INHIBITOR | SOLID TUMORS | SAFETY | 1ST-IN-HUMAN | I TRIALS | CANCER | ONCOLOGY | TYROSINE KINASE INHIBITOR | AGENTS | ESCALATION | Drugs | Schedules | Regulatory agencies | Hematology | Documents | Clinical trials | Monoclonal antibodies | FDA approval | Drug development | Drug dosages | Cancer
Journal Article
Journal Article
Cell Metabolism, ISSN 1550-4131, 04/2018, Volume 27, Issue 4, pp. 714 - 739
Journal Article
JOURNAL OF THORACIC ONCOLOGY, ISSN 1556-0864, 10/2019, Volume 14, Issue 10, pp. 1685 - 1688
Journal Article
Journal Article
Molecular Cancer Research, ISSN 1541-7786, 03/2017, Volume 15, Issue 3, pp. 317 - 327
Therapeutic targeting of the PI3K pathway is an active area of research in multiple cancer types, including breast and endometrial cancers. This pathway is... 
RAPAMYCIN | TRANSFORMATION | ADVANCED SOLID TUMORS | ONCOLOGY | PATHWAY | I PI3K INHIBITOR | 1ST-IN-HUMAN | COLON TUMORS | PHASE-I | TUMORIGENESIS | MTOR | CELL BIOLOGY
Journal Article
Seminars in Cancer Biology, ISSN 1044-579X, 2017, Volume 48, pp. 91 - 103
Journal Article
Journal Article